Date: 5 Mar 2024 (Tuesday) Time: 11:00am - 12:30pm
Hosted by: Adrian TEO, IMCB, Singapore
Ryuhei HAYASHI Osaka University, Japan
"Regenerative medicine for the eye using pluripotent stem cells"
ABSTRACT The eye is a complex organ composed of distinct cell lineages. In recent years, we have successfully induced 2D eye-like organoids named SEAM (Self-formed Ectodermal Autonomous Multi-zone), consisting of various ocular cell lineages, such as corneal and retinal progenitor cells in a well-organized manner from human pluripotent stem cells (PSCs) (Hayashi R. Nature 2016). Furthermore, we established a method for isolating induced corneal cells, and in 2019, achieved the world's first successful transplantation of human PSC-derived corneal epithelial cells to treat patients with corneal epithelial stem cell deficiency. On the other hand, by utilizing SEAM as an organoid model for human eye development, we have investigated the mechanisms underlying the development of human ocular surface cells and successfully induced conjunctival epithelial tissues (Nomi K. Cell Rep 2021) and functional 3D lacrimal gland organoids from human PSCs (Hayashi R. Nature 2022).
BIO Ryuhei Hayashi, a Professor at Osaka University Graduate School of Medicine, has been working on in vitro eye development using human pluripotent stem cells and application to regenerative medicine for the eye, particularly, for the ocular surface (Nature 2016, Nature Protoc. 2017, Sci Rep. 2018), and completed the world's first transplantation of iPS-derived corneal epithelium to the patients (2019-2022). And recently, conjunctival epithelium including goblet cells (Cell Rep. 2021, iScience 2023) and functional 3D lacrimal gland-like organoids (Nature 2022) were successfully induced from human PSCs by using the organoid technology.
Hwee Goon TAY Duke-NUS Medical School, Singapore
"Developing stem cell based therapy for retinal degeneration"
ABSTRACT Age-related macular degeneration and advanced inherited retinal diseases are the main causes of blindness that involve irreversible photoreceptor loss. Currently, no treatment exists for reversing retinal degeneration. Hence, cell replacement therapy using photoreceptors constitutes a potentially viable therapeutic approach. By recapitulating the inter-photoreceptor matrix with recombinant laminin isoforms, we have developed a novel photoreceptor differentiation method that generates photoreceptor progenitors. Sub-retinal cell transplantation in the genetic rd10 mice model showed host-graft integration with improved visual function. We have also initiated pilot study on non-human primate which is the most physiologically relevant animal model due to presence of macula. The lack of genetic NHP model has provided us an impetus to develop injury induced model containing localized photoreceptor disruption. We have preliminary data showing the assessment of visual function in the cell transplanted NHPs based on the analyses of multi-focal electroretinogram.
BIO Hwee Goon Tay is Assistant Professor at the Centre for Vision Research in DUKE-NUS Medical School. Sha also has joint appointments at the Singapore Eye Research Institute, and the Ophthalmology & Visual Sciences Academic Clinical Programme (EYE ACP) in SingHealth. Dr Tay obtained her Ph.D. from the National University of Singapore, received post-doctoral training in Upstate Medical University (NY, USA) and subsequently in DUKE-NUS Medical School. She is a recipient of Young Investigator Research Grant Award from NMRC and the Competitive Research Program Grant Award from NRF for her stem cell based work on retinal diseases. She is a co-inventor for her patented method in laminin based photoreceptor differentiation and a co-founder for Alder Therapeutics. Her group is committed to advance this innovation towards clinical trial and make significant contributions to translational scientific research in the area of regenerative medicine for retinal diseases.